Overview of Dr. Li
Dr. Jia Li is an oncologist in Commack, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and St. Catherine of Siena Hospital. She received her medical degree from Tianjin Medical University and has been in practice 22 years. She is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 82 doctors at St. Catherine of Siena Hospital who specialize in Oncology. She has more than 30 publications and over 500 citings.
Office
650 Commack Road
Commack, NY 11725
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
Tianjin Medical UniversityClass of 1995
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2010 - 2025- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 6 citationsThe effect of pre-existing mental health comorbidities on the stage at diagnosis and timeliness of care of solid tumor malignances in a Veterans Affairs (VA) medical c...Roxanne Wadia, Xiaopan Yao, Yanhong Deng, Jia Li, Steven Brad Maron
Cancer Medicine. 2015-09-01 - 150 citationsFinal analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancerStacey Stein, Edward Samuel James, Yanhong Deng, Xiangyu Cong, Jeremy S. Kortmansky
British Journal of Cancer. 2016-03-01 - 21 citationsPancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.Parisa Momtaz, Catherine A. O’Connor, Joanne F. Chou, Marinela Capanu, Wungki Park
Cancer. 2021-08-05
Journal Articles
- Macrophage Migration Inhibitory Factor Mediates Metabolic Dysfunction Induced by Atypical Antipsychotic TherapyJia Li, Lawrence Young, Richard Bucala, The Journal of Clinical Investigation
Press Mentions
Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)November 3rd, 2020- Scientists Develop Highly Effective Tumor Detection Strategy for Common Childhood Brain TumorsOctober 20th, 2020
Suny Downstate Medical Center ReviewsAugust 1st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
